What should I do if I become resistant to quizartinib?

Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by the abnormal proliferation of blast cells in the bone marrow, resulting in the suppression of normal hematopoietic function. FLT3-ITD mutation is one of the most common gene mutations in AML patients and is closely associated with a high risk of disease recurrence and poor prognosis. For FLT3-ITD mutations, Quizartinib (Quizartinib) is an oral, highly effective II type FLT3 inhibitors are widely used in the treatment of AML by selectively targeting the activity of FLT3 kinase and blocking the abnormal proliferation signals of leukemia cells.

However, with the widespread clinical application of quizartinib, the problem of drug resistance has gradually become apparent. Drug resistance may arise from a variety of mechanisms, including mutations in the FLT3 gene itself, abnormal activation of the FLT3 signaling pathway, abnormal expression of cell cycle proteins, etc. These mechanisms reduce the sensitivity of leukemia cells to quizartinib, thus affecting the therapeutic effect.

Faced with resistance to quizartinib, patients and doctors need to adopt a range of strategies to deal with it. First of all, the use of multiple targeted drug combinations can be considered. The combined use of drugs with different mechanisms of action can reduce the risk of resistance to a single drug and may overcome existing drug resistance. Secondly, drug rotation therapy is also a feasible strategy. When resistance to one targeted drug occurs, you can switch to another targeted drug with a similar mechanism of action to reactivate tumor cells that have developed resistance. In addition, the application of immunotherapy also provides new treatment options for drug resistance problems, such as immune checkpoint inhibitors. These drugs can enhance the immune system's ability to attack tumor cells.

In addition to the above strategies, patients and physicians should also pay close attention to the interactions between quizartinib and other drugs, because some drugs may affect the metabolism and clearance of quizartinib in the body, thus changing its drug concentration and efficacy. When adjusting the treatment plan, the patient's specific condition, genetic variation, liver and kidney function and other factors should be fully considered to formulate an individualized treatment plan.

In short, resistance to quizartinib is a challenge in the treatment ofAML, but through reasonable treatment strategies and drug combinations, as well as continuous disease monitoring and adjustment, patients may still be able to obtain effective treatment and control the development of the disease. At the same time, future research should continue to explore new treatment methods to delay the occurrence of Quizartinib resistance and improve the treatment effect and survival rate of AML patients.

xa0

Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC7073218/#B60-ijms-21-01537